Imaging agents:

Indications for: VISIPAQUE 320

Intra-arterial: Digital subtraction angiography, angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. IV: CT imaging of the head and body, excretory urography, and coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of suspected coronary artery disease.

Adult Dosage:

≥12yrs: Usual single doses: Intra-arterial (digital subtraction angiography): Carotid or vertebral arteries: 5–8mL (max 175mL); Aortography: 10–50mL; Major branches of aorta: 2–10mL; Aortofemoral runoffs: 6–15mL; Peripheral arteries: 3–15mL (max 250mL). Intra-arterial (arteriography): Carotid arteries: 10–14mL; Vertebral arteries: 10–12mL (max 175mL); Right coronary artery: 3–8mL; Left coronary artery: 3–10mL; Left ventricle: 20–45mL (max 200mL); Renal arteries: 8–18mL; Aortography: 30–70mL; Major branches of aorta: 10–70mL; Aortofemoral runoffs: 20–90mL; Peripheral arteries: 15–30mL (max 250mL). IV: CT of head or body: 75–150mL or 100–150mL bolus infusion; max 150mL. Excretory urography (normal renal function): 1mL/kg; max 100mL. CCTA (bolus inj with test bolus or bolus tracking): 50–150mL (4–7mL/sec); max 150mL.

Children Dosage:

<12yrs: Intra-arterial for angiocardiography, cerebral arteriography, and visceral arteriography: 1–2mL/kg; max 4mL/kg.

VISIPAQUE 320 Contraindications:

Intrathecal use.

Boxed Warning:

Not for intrathecal use.

VISIPAQUE 320 Warnings/Precautions:

Have resuscitation equipment and trained personnel available. Homocystinuria: avoid. Severe renal impairment. Cardiovascular disease. CHF. Diabetes. Advanced vascular disease. Multiple myeloma/paraproteinaceous diseases. Pheochromocytoma. Catecholamine-secreting paragangliomas. Thyroid dysfunction (esp. children 0–3yrs); monitor. Homozygous sickle cell disease. History of severe cutaneous adverse reactions: avoid. Maintain adequate hydration. Avoid extravasation. Children: asthma, cyanotic and acyanotic heart disease, CHF, serum creatinine >1.5mg/dL, immature renal function, dehydration: increased risk of adverse effects. Elderly. Pregnancy. Nursing mothers: not recommended.

See Also:

VISIPAQUE 320 Classification:

Radiographic contrast medium.

VISIPAQUE 320 Interactions:

May increase risk of metformin-induced lactic acidosis. Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Caution with concomitant beta-blockers. Do not use laxatives, diuretics, or preparatory dehydration prior to administration. Radioactive iodine uptake studies may not accurately reflect thyroid function for at least 16 days.

Adverse Reactions:

Rash, erythema, pruritus, scotoma; acute kidney injury, thromboembolic events, hypersensitivity reactions, others.

Generic Drug Availability:

NO

How Supplied:

Bottles (50mL, 100mL, 150mL, 200mL)—10